Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers

More than two-thirds of all women diagnosed with epithelial ovarian cancer (EOC) will die from the disease (>14,000 deaths annually), a fact that has not changed considerably in the last three decades. Although the 5-year survival rates for most other solid tumors have improved steadily, ovarian...

Full description

Saved in:
Bibliographic Details
Published in:Cancer prevention research (Philadelphia, Pa.) Pa.), 2020-03, Vol.13 (3), p.241-252
Main Authors: Trinidad, Camille V, Tetlow, Ashley L, Bantis, Leonidas E, Godwin, Andrew K
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - blood
Early Detection of Cancer - methods
Female
Humans
Liquid Biopsy - methods
Neoplasm Recurrence, Local - epidemiology
Neoplasm Staging
Ovarian Neoplasms - blood
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - mortality
Ovarian Neoplasms - therapy
Ovary - diagnostic imaging
Ovary - pathology
Predictive Value of Tests
Survival Rate
Ultrasonography
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:More than two-thirds of all women diagnosed with epithelial ovarian cancer (EOC) will die from the disease (>14,000 deaths annually), a fact that has not changed considerably in the last three decades. Although the 5-year survival rates for most other solid tumors have improved steadily, ovarian cancer remains an exception, making it the deadliest of all gynecologic cancers and five times deadlier than breast cancer. When diagnosed early, treatment is more effective, with a 5-year survival rate of up to 90%. Unfortunately, most cases are not detected until after the cancer has spread, resulting in a dismal 5-year survival rate of less than 30%. Current screening methods for ovarian cancer typically use a combination of a pelvic examination, transvaginal ultrasonography, and serum cancer antigen 125 (CA125), but these have made minimal impact on improving mortality. Thus, there is a compelling unmet need to develop new molecular tools that can be used to diagnose early-stage EOC and/or assist in the clinical management of the disease after a diagnosis, given that more than 220,000 women are living with ovarian cancer in the United States and are at risk of recurrence. Here, we discuss the state of advancing liquid-based approaches for improving the early detection of ovarian cancer. .
ISSN:1940-6207
1940-6215
DOI:10.1158/1940-6207.capr-19-0184